Meda has reached an agreement with Roche to acquire four of its pharmaceutical products, strengthening its key therapy areas: cardiology, CNS and pain/inflammation. Meda acquired worldwide rights to the products, with the major markets including Germany, Spain, Switzerland, the U.S. and France. The purchase price is approximately $180 million, equivalent to about two times annual sales.     The acquired products are: Marcoumar, an anticoagulant; Torem, an antihypertensive; Tilcotil, a NSAID ...